10-Q: Relay Therapeutics Narrows Q3 Loss, Extends Cash Runway

Relay Therapeutics reported a reduced net loss in Q3 2025 and for the nine months ended September 30, 2025, driven by lower operating expenses and strategic portfolio adjustments, extending its cash runway into 2029.

Summary

• Net loss for the nine months ended September 30, 2025, was $221.6 million, an improvement from $261.7 million in the same period of 2024.
• Operating expenses decreased by $47.0 million to $250.5 million for the nine months ended September 30, 2025, compared to $297.5 million in 2024.
• Research and development (R&D) expenses decreased by $45.0 million to $206.0 million for the nine months ended September 30, 2025, primarily due to streamlining the research organization and cost avoidance on lirafugratinib development.
• General and administrative (G&A) expenses decreased by $15.2 million to $44.5 million for the nine months ended September 30, 2025, mainly due to lower stock compensation and employee costs.
• Cash, cash equivalents, and investments totaled $596.4 million as of September 30, 2025, projected to fund operations into 2029.
• The Genentech Agreement for migoprotafib (RLY-1971) was terminated effective January 7, 2025, resulting in no further milestone or other payments.
• An exclusive global licensing agreement was signed with Elevar Therapeutics in December 2024 for lirafugratinib (RLY-4008), generating $8.4 million in upfront and materials transfer revenue, with potential for up to $495.0 million in milestones and tiered royalties.
• The company initiated a global Phase 3 registrational study (ReDiscover-2 Trial) for RLY-2608 plus fulvestrant in PI3K-mutated, HR+/HER2advanced breast cancer patients in Q2 2025.
• Updated interim clinical data for RLY-2608 plus fulvestrant from the ReDiscover Trial showed a 10.3-month median progression-free survival (PFS) overall and 11.0-month median PFS in second-line patients, with a generally well-tolerated safety profile.
• A global Phase 1/2 clinical trial (ReInspire Trial) for RLY-2608 in PIK3CA-related overgrowth spectrum (PROS) and malformations was initiated in Q1 2025.
• Over 70 employees were involuntarily terminated, and a $2.3 million intangible asset for the assembled workforce was impaired and written off.
• The initial research term under the D.E. Shaw Research (DESRES) Agreement ended on August 16, 2025, impacting access to certain computational power.

Sentiment

Score: 7

Explanation: The company demonstrated improved financial performance with a reduced net loss and lower operating expenses, coupled with an extended cash runway into 2029. Strategic portfolio management, including a new licensing deal and advancement of lead clinical candidates into Phase 3, indicates positive operational momentum. While significant accumulated losses and the termination of a major collaboration remain, the overall trajectory and clinical progress are favorable.

Positives

• Net loss significantly decreased for both the three-month ($74.1 million vs $88.1 million) and nine-month ($221.6 million vs $261.7 million) periods ended September 30, 2025, compared to the prior year.
• Operating expenses decreased substantially by $47.0 million for the nine months ended September 30, 2025, due to strategic streamlining and cost avoidance.
• Cash, cash equivalents, and investments of $596.4 million as of September 30, 2025, are expected to fund operations into 2029, extending the company's financial runway.
• The exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib generated $8.4 million in upfront revenue and offers potential for significant future milestone payments and tiered royalties (up to $495.0 million).
• Initiation of a global Phase 3 registrational study (ReDiscover-2 Trial) for RLY-2608 indicates significant advancement of the lead product candidate.
• Positive updated interim clinical data for RLY-2608 in breast cancer from the ReDiscover Trial showed promising median PFS (10.3 months overall, 11.0 months in second-line patients) and a generally well-tolerated safety profile.
• Initiation of a global Phase 1/2 clinical trial (ReInspire Trial) for RLY-2608 in vascular malformations expands potential indications for the lead candidate.

Negatives

• The Genentech Agreement for migoprotafib was terminated effective January 7, 2025, eliminating future milestone and other payments from that collaboration.
• Revenue for the nine months ended September 30, 2025, decreased to $8.4 million from $10.0 million in the prior year, primarily due to the Genentech termination.
• The company incurred a substantial accumulated deficit of $2.0 billion as of September 30, 2025, reflecting a history of significant operating losses.
• Over 70 employees were involuntarily terminated during the nine months ended September 30, 2025, leading to a $2.3 million impairment of an intangible asset related to the assembled workforce.
• Net cash provided by financing activities significantly decreased to $0.7 million for the nine months ended September 30, 2025, compared to $269.4 million in the prior year, indicating less capital raised through equity offerings in the current period.
• The initial research term under the D.E. Shaw Research (DESRES) Agreement ended on August 16, 2025, and the company no longer has direct access to the Anton 2 supercomputer, which was an important aspect of its Dynamo platform.

Risks

• Inability to successfully complete large-scale, pivotal clinical trials for any product candidates.
• Lengthy, expensive, and uncertain clinical product development process, potentially leading to additional costs or delays.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals.
• Positive data from preclinical or early clinical studies may not be predictive of later clinical study results.
• Current or future clinical trials may reveal significant adverse events not seen in earlier studies, inhibiting regulatory approval or market acceptance.
• Failure to identify viable new product candidates for clinical development could materially harm the business.
• Market opportunities for product candidates may be smaller than estimated, or approvals may be based on narrower patient populations, adversely affecting revenue and profitability.
• Substantial competition from other pharmaceutical and biotechnology companies.
• Inability to obtain or delays in obtaining required regulatory approvals for product candidates.
• Reliance on third parties (CROs, CMOs) to conduct clinical trials and manufacturing, increasing risks of non-compliance, missed deadlines, or insufficient quantities/quality.
• Product candidates utilize novel mechanisms of action and binding locations, potentially leading to greater R&D expenses, regulatory issues, or unknown adverse effects.
• FDA or similar foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Uncertainty regarding insurance coverage and reimbursement for newly-approved products.
• Potential for disputes or termination of license and collaboration agreements (e.g., Genentech termination, DESRES Agreement).
• Need to raise substantial additional funding, with potential for dilution or restrictive covenants.
• Impact of future pandemics, epidemics, or infectious disease outbreaks on business operations and clinical trials.
• Adverse effects of global economic and political conditions, including interest rates, credit market instability, and geopolitical conflicts.
• Significant political, trade, and regulatory developments (e.g., changes in U.S. federal administration policies, tariffs, Inflation Reduction Act, Executive Orders on drug pricing).
• Inability to adequately protect proprietary technology or obtain and maintain patent protection, or if the scope of protection is not sufficiently broad.
• Intellectual property litigation, including claims of infringement by third parties or challenges to the company's patents.
• Inability to protect the confidentiality of trade secrets.
• Failure to secure trademark registrations.
• Inability to effectively enforce intellectual property rights globally.
• Failure to obtain patent term extension and data exclusivity.
• Need to license intellectual property from third parties, which may not be available on commercially reasonable terms.
• Failure to comply with obligations in collaboration or license agreements.
• Ongoing regulatory obligations and continued regulatory review post-approval, with potential for post-market study requirements, marketing/labeling restrictions, or recall.
• Risks associated with promoting off-label uses.
• Compliance with evolving data collection and privacy regulations (GDPR, UK GDPR, CCPA, CPRA, MHMDA).
• Risks and challenges associated with the use of new and evolving technologies, such as artificial intelligence.
• Difficulties in attracting, retaining, and motivating qualified scientific and clinical personnel.
• Risk of employee misconduct or other improper activities.
• Increasing use of social media platforms presenting risks and challenges.
• Impact of environmental, social, and governance (ESG) matters on business and reputation.
• Difficulties in managing growth and integrating potential acquisitions.
• Failure or cybersecurity breaches of internal information technology systems or those of third parties.
• Failure to comply with environmental, health, and safety laws and regulations.
• Adverse effects of natural disasters or other unplanned events.
• Volatility in the trading price of common stock and potential for securities class action litigation.
• No cash dividends anticipated.
• Significant control by executive officers, directors, principal stockholders, and their affiliates.
• Limitations on the ability to utilize net operating loss carryforwards due to ownership changes (Section 382).
• Adverse effects of tax reform legislation.
• Significant costs and management time associated with operating as a public company and compliance initiatives (Sarbanes-Oxley, Section 404).
• Anti-takeover provisions in charter documents and Delaware law.
• Designation of exclusive forums for certain litigation.
• Impact of securities analysts' research and reports on stock price.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its lead product candidate, RLY-2608, through clinical trials (including the global Phase 3 ReDiscover-2 Trial and Phase 1/2 ReInspire Trial), conducts preclinical research for other programs (RLY-8161, Fabry disease, early-stage discovery), and pursues marketing approvals. Expenses are anticipated to increase with potential commercialization efforts, manufacturing, intellectual property protection, hiring, and facility expansion. The company believes its existing cash, cash equivalents, and investments of $596.4 million as of September 30, 2025, will fund operations into 2029, but acknowledges the need for substantial additional financing in the future, which may involve equity or debt financings or collaborations.

Management Comments

• "We believe we are among the first of a new breed of biotech created at the intersection of complementary techniques and technologies, we aim to push the boundaries of what's possible in drug discovery."
• "We believe that, overall, while the clinical data from the ReDiscover Trial disclosed to date are preliminary, the data suggest differentiated interim efficacy signals in the specified patient population and support selective target engagement across doses and mutation types with an encouraging interim safety and tolerability profile."
• "We are focused on using the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of our therapies."
• "We expect to continue to incur significant expenses, including the costs of operating as a public company, and generate significant operating losses for at least the next several years."
• "We believe our cash, cash equivalents, and investments of $596.4 million as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements into 2029."

Industry Context

Relay Therapeutics operates in the highly competitive biopharmaceutical industry, specifically focusing on precision medicine, targeted oncology, and genetic diseases using its proprietary Dynamo platform. The industry is characterized by extensive R&D, high capital requirements, and significant regulatory hurdles. The company's strategic shift, including the termination of the Genentech collaboration and the licensing of lirafugratinib to Elevar, reflects a common industry practice of portfolio optimization and leveraging partnerships to manage development costs and focus resources on lead assets like RLY-2608. The initiation of a Phase 3 trial for RLY-2608 positions it against established and emerging therapies in breast cancer, such as capivasertib, highlighting the intense competition for market share in oncology. The company's reliance on novel mechanisms of action and computational drug discovery aligns with broader industry trends towards AI/ML-driven drug development, though this also introduces unique regulatory and development risks. The ongoing challenges of inflation, global economic uncertainty, and evolving regulatory landscapes (e.g., drug pricing legislation like the IRA) are pervasive industry-wide factors impacting all players.

Comparison to Industry Standards

• RLY-2608 is positioned as the first known allosteric, pan-mutant and isoform-selective PI3K inhibitor in clinical development, suggesting a potentially differentiated mechanism compared to existing or pipeline PI3K inhibitors.
• The ReDiscover-2 Trial for RLY-2608 plus fulvestrant in PI3K-mutated, HR+/HER2advanced breast cancer patients previously treated with a CDK4/6 inhibitor uses capivasertib plus fulvestrant as a comparator arm. Capivasertib (AstraZeneca) is an AKT inhibitor, often used in PI3K-mutated breast cancer, indicating Relay is directly comparing its novel PI3K inhibitor against a relevant, established competitor in a late-stage setting.
• The reported 10.3-month median progression-free survival (PFS) overall and 11.0-month median PFS in second-line patients with PI3K-mutated, HR+/HER2metastatic breast cancer from the ReDiscover Trial are preliminary but suggest competitive efficacy signals. For context, alpelisib (Piqray), another PI3K inhibitor approved for a similar population, showed a median PFS of 11.0 months in the PIK3CA-mutated cohort of the SOLAR-1 trial. This suggests RLY-2608's interim data is in a comparable range, with the added benefit of a 'generally well tolerated' safety profile, which could be a key differentiator if sustained.
• The termination of the Genentech Agreement for migoprotafib (RLY-1971) and the licensing of lirafugratinib (RLY-4008) to Elevar Therapeutics are examples of portfolio rationalization, a common strategy in the biopharmaceutical industry to focus resources on high-potential assets and manage R&D costs, especially for companies with limited operating histories and significant accumulated deficits.

Management Changes

Legal Proceedings

• A derivative complaint was filed on December 18, 2024, by David Hayes, an alleged stockholder, against certain directors and officers.
• The complaint alleges excessive compensation awarded to Board of Directors members in 2021, 2022, and 2023.
• Claims include breach of fiduciary duty, unjust enrichment, waste of corporate assets, and breach of fiduciary duty of disclosure.
• The plaintiff seeks damages, reform of corporate governance and internal procedures, restitution, disgorgement of profits, and legal fees.
• The company and defendants answered the complaint on January 24, 2025, and the case is currently in discovery.
• The outcome, reasonably possible loss, or range of loss related to this matter is currently unpredictable.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; stock price volatility; impact from legal proceedings against directors/officers; potential for long-term value creation if product candidates succeed.
• Employees: Over 70 involuntary terminations occurred, impacting job security and potentially morale; ongoing competition for qualified personnel.
• Customers (future patients): Potential for life-changing therapies if product candidates are successfully developed and commercialized; risks of delays or failures in clinical trials.
• Suppliers/CROs/CMOs: Continued reliance on third parties for R&D and manufacturing, subject to their performance and compliance.
• Creditors: The company's ability to raise additional capital and achieve profitability will impact its long-term financial viability.

Next Steps

• Continue enrollment in the global Phase 1/2 ReInspire Trial for RLY-2608 in PIK3CA-related overgrowth spectrum and malformations.
• Advance the global Phase 3 registrational ReDiscover-2 Trial for RLY-2608 plus fulvestrant in PI3K-mutated, HR+/HER2advanced breast cancer patients.
• Progress the NRAS-selective inhibitor, RLY-8161, to address NRAS-mutated solid tumors.
• Progress the non-inhibitory chaperone for Fabry disease.
• Continue early-stage discovery programs.
• Seek additional financing through public/private equity, debt, or collaborations to support ongoing and future operations.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statements.

Key Dates

Recommendation

Relay Therapeutics shows promising clinical progress with RLY-2608 advancing to Phase 3 and positive interim data, alongside strategic financial management that has reduced net losses and extended its cash runway into 2029. The licensing deal with Elevar also provides non-dilutive capital and future milestone potential. However, the company remains in a clinical stage with a substantial accumulated deficit and will require significant additional funding. The termination of the Genentech collaboration and the loss of direct access to the Anton 2 supercomputer from DESRES are notable setbacks. The ongoing derivative lawsuit against directors and officers adds a layer of uncertainty. Given the early stage of commercialization, the inherent risks of drug development, and the need for future capital, a 'hold' recommendation is appropriate. Investors should monitor the progress of RLY-2608's Phase 3 trial, the development of other pipeline candidates, and future financing activities.

Keywords

Precision Medicine, Oncology, Genetic Disease, Drug Discovery, Clinical Stage, RLY-2608, PI3K Inhibitor, Breast Cancer, Vascular Malformations, Dynamo Platform, Biopharmaceutical, SEC Filing, 10-Q, Financial Results, Clinical Trials, Biotech, Pharmaceutical, RLAY